[HTML][HTML] Response and resistance to BCR-ABL1-targeted therapies
TP Braun, CA Eide, BJ Druker - Cancer cell, 2020 - cell.com
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …
kinase, has served as a paradigm for successful application of molecularly targeted cancer …
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Acute lymphoblastic leukemia in children
SP Hunger, CG Mullighan - New England Journal of Medicine, 2015 - Mass Medical Soc
Acute Lymphoblastic Leukemia in Children | New England Journal of Medicine Skip to main
content The New England Journal of Medicine homepage Advanced Search SEARCH …
content The New England Journal of Medicine homepage Advanced Search SEARCH …
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells
Abstract Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other
second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has …
second-and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has …
Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia
G Etienne, J Guilhot, D Rea, F Rigal-Huguet… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
(CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years …
[HTML][HTML] Chronic myeloid leukemia: a model disease of the past, present and future
VR Minciacchi, R Kumar, DS Krause - Cells, 2021 - mdpi.com
Chronic myeloid leukemia (CML) has been a “model disease” with a long history. Beginning
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …
with the first discovery of leukemia and the description of the Philadelphia Chromosome and …
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob… - Nature, 2017 - nature.com
Chronic myeloid leukaemia (CML) is driven by the activity of the BCR–ABL1 fusion
oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with …
oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with …
Tyrosine kinase inhibitor–associated cardiovascular toxicity in chronic myeloid leukemia
JJ Moslehi, M Deininger - Journal of clinical oncology, 2015 - ascopubs.org
For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have
turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI …
turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI …
Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology
JP Radich, M Deininger, CN Abboud, JK Altman… - Journal of the National …, 2018 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …